News

CavoGene LifeSciences is going to explore a new gene therapy, called SynCav1, that may represent an alternative and attractive strategy to treat several neurodegenerative diseases, including Alzheimer’s. This follows CavoGene’s acquisition of SynCav1’s developmental and commercialization rights from the University of California San Diego. SynCav1 was designed to specifically…

Commonly used antidepressants known as selective serotonin reuptake inhibitors, or SSRIs, can prevent beta-amyloid aggregation, representing a potential new therapeutic strategy for Alzheimer’s disease, a study suggests. The study, “Interactions of Selective Serotonin Reuptake Inhibitors with β-Amyloid,” was published in ACS Chemical Neuroscience.

A study has identified two forms of glutathione (GSH) — an important antioxidant that protects the brain from harmful free radicals — in the brains of living people using a non-invasive technique. It also found one form of GSH at levels significantly lower than usual in people with Alzheimer’s disease (AD).

A newly developed antibody targeting a protein called fibrin was seen to prevent inflammation and oxidative stress induced by amyloid aggregates in the brains of a mouse model of Alzheimer’s disease. These findings may pave the way for a new way of treating and preventing the neurodegeneration associated with Alzheimer’s…

A protein that’s involved in calcium transport within nerve cells was linked to sporadic Alzheimer’s disease by scientists working in Spain. This protein, called STIM1, may hold promise as a biomarker of this common and non-familial form of Alzheimer’s. Importantly, common treatments for hypertension that are based on dihydropyridine — and…

Using a technique called genome-wide mapping, researchers were able to identify specific variations in RNA splicing from brain tissue taken from 450 people who were part of clinical studies into aging. This work — which identified hundreds of altered splicing events, which affect protein production — in Alzheimer’s, and may…

High levels of free triiodothyronine — a type of thyroid hormone — are associated with a lower rate of Alzheimer’s disease risk in patients who have subjective or objective mild cognitive impairment, a new study shows. The study, “Low serum concentration of free triiodothyronine (FT3) is associated with increased risk of…

A dietary supplement made with components of foods such as broccoli and peppers plus fish oil may help slow the progression of Alzheimer’s disease and improve memory, sight and mood, a small clinical trial suggests. The findings paved the way for a larger European trial, called re-MIND, currently recruiting…

The Alzheimer’s Foundation of America (AFA) is lauding the additional $425 million designated for Alzheimer’s disease research contained in the Sept. 26 passage of the Health and Human Services (HHS) budget for fiscal year 2019. Its passage brings federal funding to fight the disease to $2.34 billion. “AFA…

Researchers have discovered a new mechanism targeted by the leukemia therapy Sprycel that may contribute to Alzheimer’s and traumatic brain injury. The team, which effectively targeted this mechanism in a mouse model of Alzheimer’s, now hopes to replicate the test in humans. The study, “Oxidation of…